Roche and Epigenomics entered into 3-year R&D collaboration to develop non-invasive diagnostic products for the early detection of colon, breast and prostate cancers. The deal could be worth up to US$106.4 M and involves utilizing Epigenomics’ DNA methylation technology that will be incorporated into Roche’s PCR platforms and microarray technology.